RxSight, Inc. (RXST)
- Previous Close
48.51 - Open
48.85 - Bid --
- Ask --
- Day's Range
48.85 - 50.24 - 52 Week Range
20.66 - 66.54 - Volume
233,458 - Avg. Volume
480,476 - Market Cap (intraday)
1.967B - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.99 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
64.86
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
www.rxsight.comRecent News: RXST
View MorePerformance Overview: RXST
Trailing total returns as of 10/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RXST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RXST
View MoreValuation Measures
Market Cap
1.93B
Enterprise Value
1.70B
Trailing P/E
--
Forward P/E
105.26
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.47
Price/Book (mrq)
6.99
Enterprise Value/Revenue
14.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-31.93%
Return on Assets (ttm)
-10.58%
Return on Equity (ttm)
-17.01%
Revenue (ttm)
115.18M
Net Income Avi to Common (ttm)
-36.77M
Diluted EPS (ttm)
-0.99
Balance Sheet and Cash Flow
Total Cash (mrq)
233.28M
Total Debt/Equity (mrq)
4.15%
Levered Free Cash Flow (ttm)
-19.18M